CRISPR Therapeutics increases its Series B to a Massive €125M
Everyone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech…
The gene-editing tool CRISPR-Cas9 has taken over the life sciences world since its development in 2012. CRISPR has changed the way biology research is done, simplifying and speeding up the study of diseases and the discovery of drugs, as well as having a huge impact on crop and food development. Among all its possible applications, the fact that CRISPR can be used to tweak the human genome has made it especially promising for previously difficult-to-treat diseases.
But how does CRISPR work? What kind of therapies are being developed? How is the genome-editing market evolving? And how are stakeholders navigating the complex intellectual property around this technology? Find out the answers to these questions and more on this page.
The Genome Editing Toolbox: ZFNS, TALENS, and CRISPR in Biomedicine
This report covers the industry’s most common genome-editing tools, like CRISPR-Cas9, provides exclusive insights by experts, looks at the market, and addresses future applications and challenges of genome-editing tools.
Go to ReportEveryone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech…
CRISPR has received a regulatory green light in what could be the first clinical trial with…
CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle…
So begins our series of videos documenting our biotech conference premier - Labiotech Refresh. Here…
Bayer has signed a patent license agreement with ERS Genomics, that controls patents for the…
The research team led by Emannuelle Charpentier, co-discoverer of the CRISPR/Cas9 system, has found that…
CRISPR remains in the spotlight as the scientific discovery of the century. A long list…
MIMIVIRE is the name French researchers have given to the immunity mechanism of mimivirus, and…
Desktop Genetics, a small bioinformatics start-up out of London, has won a substantial grant to…
This could be a HUGE game-changer for Europe's research on stem cells, and more broadly Gene…
The crisis of 2008 hit the Biotech sector hard, and it wasn't clear how the…
Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in…